Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Jan 19, 2021 7:27pm
106 Views
Post# 32330196

RE:RE:RE:RE:more insider buying ...

RE:RE:RE:RE:more insider buying ...
Doccole wrote: I appreciate the resource.


No problem Doccole.

I am closely watching Goodman to see if he pulls the trigger on additional ATE geographies, This would be a huge win-win for the two companies.

The future of pain and inflammation, the doorway to virus therapeutics, central sleep apnea meds, certain cancers, alzheimer's and the list goes on.  I see Aspirin as a whole industry on it's own, tailored like vitamins to keep us healthier as we age.  Oh ya ... don't forget the anti-aging properties of H2S ... that's really what makes it so wonderful.

But ... can Goodman seal the deal ?  

It is the biggest and best opportunity facing GUD right now and it would have huge implications for future sales.  I'd like to think Goodman has been laser focused on it since the day he left their Board of Directors. 

2021 should be telling.



: )      Hahaha !!!!  Keep the dream alive folks !!!
<< Previous
Bullboard Posts
Next >>